<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03467217</url>
  </required_header>
  <id_info>
    <org_study_id>9 STOP-NAFLD</org_study_id>
    <secondary_id>U01DK061730</secondary_id>
    <nct_id>NCT03467217</nct_id>
  </id_info>
  <brief_title>Losartan for the Treatment of Pediatric NAFLD</brief_title>
  <acronym>STOP-NAFLD</acronym>
  <official_title>Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double masked, placebo-controlled, parallel treatment groups phase
      2 trial of losartan for pediatric nonalcoholic fatty liver disease (NAFLD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children ages 8-17 years weighing between 70 -149 kilograms will be enrolled and treated with
      losartan (100 mg orally once per day) or matching placebo for 24 weeks. The hypothesis is
      that losartan will improve serum alanine aminotransferase (ALT) in children with pediatric
      NAFLD.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 16, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Participants, investigators, clinical staff, and data monitoring committee will not have knowledge of the interventions assigned to individual participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in serum alanine aminotransferase (ALT) from baseline.</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALT value in U/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative change in serum alanine aminotransferase (ALT) compared to baseline ALT</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALT value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving normalization of ALT</measure>
    <time_frame>24 weeks</time_frame>
    <description>ALT value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum aspartate aminotransferase AST at 24 weeks compared to baseline AST</measure>
    <time_frame>24 weeks</time_frame>
    <description>AST value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gamma-glutamyl transpeptidase (GGT) compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT at 12 weeks compared to baseline ALT</measure>
    <time_frame>12 weeks</time_frame>
    <description>ALT value in U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) compared to baseline.</measure>
    <time_frame>24 weeks</time_frame>
    <description>is an equation which indicates the degree of insulin resistance, where higher scores equate to greater insulin resistance. HOMA-IR is calculated as fasting (Glucose (mmol/L) x insulin (pmol/L))/22.5. A HOMA-IR value &gt;2.0 in prepubertal children and &gt;2.6 in pubertal children, may be considered a warning sign for pediatricians to further investigate insulin resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight (kg)</measure>
    <time_frame>24 weeks</time_frame>
    <description>kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body-mass Index Z- Score</measure>
    <time_frame>24 weeks</time_frame>
    <description>Body mass index z-scores is calculated using age, gender, height and weight and calculated using 2000 CDC Growth Charts for norms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist circumference</measure>
    <time_frame>24 weeks</time_frame>
    <description>centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist -hip ratio</measure>
    <time_frame>24 weeks</time_frame>
    <description>ratio of the circumference of the waist to that of the hips. This is calculated as waist measurement divided by hip measurement (W ÷ H).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum lipid profiles compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>lipid profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pediatric Quality of Life Inventory (PedsQL) Score scores compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>Pediatric Quality of Life Inventory (PedsQL) version 4.0 is completed by both the child and parent/caregiver, and is composed of 23 items comprising 4 dimensions: Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. Scores are transformed on a scale from 0 to 100, with higher scores indicating better health-related quality of life. Physical Health Summary Score =Physical Functioning Scale Score. Psychosocial Health Summary Score = Sum of items over the number of items answered in the Emotional, Social, and School Functioning Scales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of adverse events compared to baseline</measure>
    <time_frame>24 weeks</time_frame>
    <description>Numbers of adverse events reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>NAFLD - Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Losartan potassium capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose will be one 50 mg capsule of losartan per day for one week and then increased to two capsules of 50 mg of losartan per day (100 mg total) for 23 weeks patients with baseline weight ≥ 70 kg to &lt;150 kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo losartan capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose will be one 50 mg capsule of placebo losartan per day for one week and then increased to two capsules of 50 mg of placebo losartan per day (100 mg total) for 23 weeks for patients with baseline weight ≥ 70 kg to &lt;150 kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan potassium</intervention_name>
    <description>Losartan potassium is an angiotensin II receptor blocker acting on the AT 1 receptor subtype</description>
    <arm_group_label>Losartan potassium capsule</arm_group_label>
    <other_name>losartan, Cozaar,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo losartan capsule</intervention_name>
    <description>Matching placebo losartan oral capsule</description>
    <arm_group_label>Placebo losartan capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 8-17 years at initial screening interview

          -  Histological evidence of NAFLD with or without fibrosis and a NAFLD activity score
             (NAS) of ≥3, on a liver biopsy obtained no more than 730 days prior to enrollment.

          -  Serum ALT at screening ≥ 50 IU/L

        Exclusion Criteria:

          -  Body weight less than 70 kg or greater than 150 kg at screening

          -  Significant alcohol consumption or inability to reliably quantify alcohol intake

          -  Use of drugs historically associated with NAFLD (amiodarone, methotrexate, systemic
             glucocorticoids, tetracyclines, tamoxifen, estrogens at doses greater than those used
             for hormone replacement, anabolic steroids, valproic acid, other known hepatotoxins)
             for more than 2 consecutive weeks in the past year prior to randomization

          -  New treatment with vitamin E or metformin started in the past 90 days or plans to
             alter the dose or stop over the next the 24 weeks. A stable dose is acceptable.

          -  Prior or planned bariatric surgery

          -  Uncontrolled diabetes (HbA1c 9.5% or higher)

          -  Presence of cirrhosis on liver biopsy

          -  History of hypotension or history of orthostatic hypotension

          -  Stage 2 Hypertension or &gt;140 systolic or &gt;90 diastolic at screening

          -  Current treatment with any antihypertensive medications including all angiotensin
             converting enzyme (ACE) inhibitors or aliskiren

          -  Current treatment with potassium supplements or any drug known to increase potassium

          -  Current daily use of nonsteroidal anti-inflammatory drugs (NSAIDs)

          -  Current treatment with lithium

          -  Platelet counts below 100,000 /mm3

          -  Clinical evidence of hepatic decompensation (serum albumin &lt; 3.2 g/dL, international
             normalized ratio (INR) &gt;1.3, direct bilirubin &gt;1.3 mg/dL, history of esophageal
             varices, ascites, or hepatic encephalopathy)

          -  Evidence of chronic liver disease other than NAFLD:

               -  Biopsy consistent with histological evidence of autoimmune hepatitis

               -  Serum hepatitis B surface antigen (HBsAg) positive.

               -  Serum hepatitis C antibody (anti-HCV) positive.

               -  Iron/total iron binding capacity (TIBC) ratio (transferrin saturation) &gt; 45% with
                  histological evidence of iron overload

               -  Alpha-1-antitrypsin (A1AT) phenotype/genotype ZZ or SZ

               -  Wilson's disease

          -  Serum alanine aminotransferase (ALT) greater than 300 IU/L

          -  History of biliary diversion

          -  History of kidney disease and/or estimated glomerular filtration rate (eGFR) &lt; than 60
             mL/min/1.73 m2 using Schwartz Bedside GFR Calculator for Children isotope dilution
             mass spectroscopy (IDMS)-traceable

          -  Known Human Immunodeficiency Virus (HIV) infection

          -  Active, serious medical disease with life expectancy less than 5 years

          -  Active substance abuse including inhaled or injected drugs, in the year prior to
             screening

          -  Pregnancy, planned pregnancy, potential for pregnancy and unwillingness to use
             effective birth control during the trial, breast feeding

          -  Participation in an IND trial in the 150 days prior to randomization

          -  Any other condition which, in the opinion of the investigator, would impede compliance
             or hinder completion of the study

          -  Inability to swallow capsules

          -  Known allergy to losartan potassium or other angiotensin receptor blocker

          -  Failure of parent or legal guardian to give informed consent or subject to give
             informed assent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Doo, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Janis Durelle</last_name>
      <phone>619-543-5226</phone>
      <email>jdurelle@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Schwimmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille Langlois</last_name>
      <phone>415-476-1756</phone>
      <email>Camille.Langlois@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Rosenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miriam Vos, MD, MSPH</last_name>
      <phone>404-727-1463</phone>
      <email>Mvos@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Cleeton</last_name>
      <phone>(404) 727-5383</phone>
      <email>rcleeto@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Miriam Vos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ-Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joy Ito</last_name>
      <phone>312-227-4559</phone>
      <email>jito@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Riordan</last_name>
      <phone>(312) 227.4558</phone>
      <email>mriordan@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Fishbein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Klipsch</last_name>
      <phone>317-274-9605</phone>
      <email>aeye@iupui.edu</email>
    </contact>
    <contact_backup>
      <last_name>Laura Walker</last_name>
      <phone>(317) 944-4490</phone>
      <email>walkerlk@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jean Molleston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Reynoso</last_name>
      <phone>212-305-6274</phone>
      <email>er2564@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Joel Lavine, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>April Carr</last_name>
      <phone>513-803-7744</phone>
      <email>april.carr@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Kimberlee Bernstein, BS, CCRP</last_name>
      <phone>(513)636-4406</phone>
      <email>Kimberlee.bernstein@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Stavra Xanthakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamir Miloh, MD</last_name>
      <phone>832-822-3648</phone>
      <email>tamiloh@texaschildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Alicia Lawson</last_name>
      <phone>(832) 824-3848</phone>
      <email>alicia.lawson@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tamir Miloh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://jhuccs1.us/nash/open/centers/centers.htm</url>
    <description>Nonalcoholic Steatohepatitis Clinical Research Network Centers</description>
  </link>
  <link>
    <url>http://www2.niddk.nih.gov/</url>
    <description>The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Losartan</keyword>
  <keyword>Nonalcoholic Fatty Liver Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This study will comply with the NIH Data Sharing Policy and Results information from this trial will be submitted to ClinicalTrials.gov and a public use database deposited with the NIDDK Central Repository.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

